
Pfizer, the new master of mRNA delivery, teams up with Beam to ship base editors straight to target tissues
Awash in cash from its Covid-19 vaccine and leaner than ever, Pfizer has pick of the litter in biotech for deals set to shape its portfolio for the next 10 to 15 years. Gene editing has a ton of momentum right now, and Pfizer is biting in a big way on a buzzy upstart working on “CRISPR 2.0.”
Pfizer will pay $300 million upfront and up to $1.05 billion in additional downstream milestones to Beam Therapeutics as part of a four-year research collaboration to develop base editors for a trio of therapeutic targets including the liver, CNS and muscle, the partners said Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.